JIMT-1 cells
Catalog #:
C0006005
Use only Express Delivery (overnight) for cell lines. International shipping rate please contact us for detailsShipping advice:
| Frozen vial | USD430.0 |
 |
Disease:
Breast carcinoma
Established from pleural effusions of a breast cancer patient (grade 3 invasive, T2N1M0)
Homo sapiens
Breast, mammary gland
Epithelial
Adherent
Human flat-moded highly rearranged hyperdiploid karyotype with 6% polyploidy - 46-56<2n>XX, +1, +2, +2, +3, +5, +6, +7, +12, -13, -14, -15, -15, -16, -18, +17, +5mar, add(X)(p22.1), add(1)(q11), del(1)(q32.2), der(1)add(1)(p21)add(1)(q22), der(1)t(1;6)(p11;q1?1)t(6;5)(q25;?p13), add(2)(q11)x2, t(2;3)(q10;p10)add(2)(q25-31), add(3)(p11), der(4)t(?3;4)(?q24;p11), add(5)(q15), der(5)add(5)(p15.3)del(5)(q22), der(5)t(5;8)(p11;p11), add(6)(p11)add(6)(q23), der(7)t(1;7)(p13;q21), der(7)t(7;?12)(p11;p11), add(8)(p11), i(8q) add(9)(p11), der(9)add(9)(p11)add(9)(q23), add(11)(p13), der(11)dup(11)(p11p15)add(11)(p15), der(11)t(1;11)(q24;p12), add(12)(q21), der(12;?15)(p11;q11), add(17)(p11), add(17)(p13), der(17)add(17)(p11)add(17)(q21)
Female, 62 yrs of age
AddexBio-formulated DMEM (C0003-01) + 10% FBS
1:2 to 1:6 (80-90%);using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37°C
Complete culture medium supplemented with 5% (v/v) DMSO
I
Bacteria: Negative
Yeast: Negative
Mycoplasma: Negative
HIV: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Amelogenin: X,X
CSF1PO: 12,13
D13S317: 8,13
D16S539: 11,11
D5S818: 12,13,14
D7S820: 12,12
THO1: 7,7
TPOX: 8,8
vWA: 18,18
If use of this culture results in a scientific publication, it should be cited in the publication as: JIMT-1 (AddexBio C0006005)
Origin:
Species:
Tissue:
Morphology:
Properties:
Cytogenic data:
Patient:
Medium:
Subculture:
Freezing Medium:
Biosafety Level:
Sterility:
Pathogens:
Protein Expression:
cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin -
DNA Profile (STR):
Citation Format:
Related cells by Organ:
References for JIMT-1 cells:
1. Barok, M., Isola, J., Palyi-Krekk, Z., Nagy, P., Juhasz, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., and Szollosi, J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther, 6: 2065-2072, 2007.
2. McCluskey AJ, et al. Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen. Mol Oncol., Jun;7(3):440-51, 2013 PMID: 23290417
3. Andrew J, et al. Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol Cancer Ther. Oct;12(10):2273-81, 2013 PMID: 23945077
4. Bhinder B, Shum D, Li M, Ibanez G, Vlassov AV, Magdaleno S, Djaballah H. Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens. PLoS One. 2014 Jul 2;9(7):e100676. PMID: 24987961
5. Yeh ES, Abt MA, Hill EG. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. Breast Cancer Res Treat. 2015 Jan;149(1):91-98. PMID: 25515931
6. Colombo M, Fiandra L, Alessio G, Mazzucchelli S, Nebuloni M, De Palma C, Kantner K, Pelaz B, Rotem R, Corsi F, Parak WJ, Prosperi D. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat Commun. 2016 Dec 19;7:13818. doi: 10.1038/ncomms13818. PMID: 27991503
7. Yeh ES, Williams CJ, Williams CB, Bonilla IV, Klauber-DeMore N, Phillips SL. Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration. Oncotarget. 2017 Nov 25;8(65):109358-109369. PMID: 29312613
